Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Adamas Pharmaceuticals Inc | adms10k2020ex321.htm |
| 10-K - 10-K - Adamas Pharmaceuticals Inc | adms-20201231.htm |
| EX-31.2 - EX-31.2 - Adamas Pharmaceuticals Inc | adms10k2020ex312.htm |
| EX-31.1 - EX-31.1 - Adamas Pharmaceuticals Inc | adms10k2020ex311.htm |
| EX-23.1 - EX-23.1 - Adamas Pharmaceuticals Inc | adms10k2020ex231.htm |
| EX-21.1 - EX-21.1 - Adamas Pharmaceuticals Inc | adms10k2020ex211.htm |
| EX-10.31 - EX-10.31 - Adamas Pharmaceuticals Inc | adms10k2020ex1031.htm |
| EX-10.19 - EX-10.19 - Adamas Pharmaceuticals Inc | adms10k2020ex1019.htm |
| EX-10.6 - EX-10.6 - Adamas Pharmaceuticals Inc | adms10k2020ex106.htm |
| EX-2.1 - EX-2.1 - Adamas Pharmaceuticals Inc | adms10k2020ex21.htm |
Exhibit 10.22
COMPENSATION ARRANGEMENTS WITH EXECUTIVE OFFICERS
Annual Cash Compensation
The Compensation Committee of the board of directors sets the annual base salary for each of Adamas Pharmaceuticals, Inc.’s executive officers. The annual base salary and target bonus award percentage for the executive officers, to be effective March 1, 2021, are as follows:
| Executive Officer | Annual Base Salary | Target Bonus Award % | |||||||||||||||
| Neil F. McFarlane | $643,800 | 60% | |||||||||||||||
| Vijay Shreedhar | $447,000 | 45% | |||||||||||||||
| Christopher B. Prentiss | $412,000 | 40% | |||||||||||||||